0001209191-19-042379.txt : 20190717 0001209191-19-042379.hdr.sgml : 20190717 20190717162650 ACCESSION NUMBER: 0001209191-19-042379 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190715 FILED AS OF DATE: 20190717 DATE AS OF CHANGE: 20190717 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Conner Edward R. CENTRAL INDEX KEY: 0001691265 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37833 FILM NUMBER: 19959390 MAIL ADDRESS: STREET 1: 501 CANAL BLVD. STREET 2: POINT RICHMOND TECH CENTER CITY: RICHMOND STATE: CA ZIP: 94804 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Audentes Therapeutics, Inc. CENTRAL INDEX KEY: 0001628738 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 461606174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 600 CALIFORNIA ST., 17TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94108 BUSINESS PHONE: 415-638-6556 MAIL ADDRESS: STREET 1: 600 CALIFORNIA ST., 17TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94108 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-07-15 0 0001628738 Audentes Therapeutics, Inc. BOLD 0001691265 Conner Edward R. C/O AUDENTES THERAPEUTICS, INC. 600 CALIFORNIA STREET, 17TH FLOOR SAN FRANCISCO CA 94108 0 1 0 0 SVP, Chief Medical Officer Common Stock 2019-07-15 4 A 0 30000 0.00 A 30000 D Stock Option (Right to Buy) 36.08 2019-07-15 4 A 0 90000 0.00 A 2029-07-15 Common Stock 90000 90000 D Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock upon settlement for no consideration. The RSUs will vest as to 25% of the award on September 5, 2020, and then 6.25% of the RSUs will vest quarterly thereafter on each of December 5, March 5, June 5, and September 5 of a given calendar year, such that the RSUs are fully vested on September 5, 2023, subject to the Reporting Person's provision of services to the issuer on each vesting date. Shares of the issuer's Common Stock will be delivered to the Reporting Person following vesting. The options will vest as to 25% of the total shares on July 15, 2020, and then 2.0833% of the shares will vest monthly thereafter such that the option is fully vested on July 15, 2023, subject to the Reporting Person's provision of service to the issuer on each vesting date. /s/ Mark Meltz, as Attorney-in-Fact for Edward R. Conner 2019-07-17